Empagliflozin 25 mg, sold under the brand name Jardiance, is a once-daily tablet used to treat type 2 diabetes, heart failure, and chronic kidney disease. It’s the higher of two available doses (10 mg and 25 mg) and is typically prescribed when the starting dose hasn’t brought blood sugar levels to target. Beyond blood sugar control, this medication has proven benefits for the heart and kidneys that have made it one of the most widely prescribed drugs in its class.
FDA-Approved Uses
Empagliflozin has four distinct approved uses, which is unusual for a medication originally developed as a diabetes drug:
- Type 2 diabetes: As an add-on to diet and exercise, it improves blood sugar control in adults and children aged 10 and older with type 2 diabetes.
- Heart failure: It reduces the risk of cardiovascular death and hospitalization in adults with heart failure, regardless of whether they have diabetes.
- Chronic kidney disease: It slows kidney function decline and reduces the risk of end-stage kidney disease in adults whose CKD is at risk of getting worse.
- Cardiovascular protection in diabetes: It reduces the risk of cardiovascular death in adults who have both type 2 diabetes and established heart disease.
The heart failure and kidney disease uses are notable because they apply even if you don’t have diabetes. This expanded role reflects a broader shift in how this class of drugs is used in medicine.
How It Works
Empagliflozin belongs to a class of drugs called SGLT2 inhibitors. It works by blocking a protein in your kidneys that normally reabsorbs sugar back into your bloodstream. With that protein blocked, excess glucose leaves your body through urine instead of recirculating. This lowers blood sugar without relying on insulin, which is a fundamentally different approach from most other diabetes medications.
The same kidney mechanism also reduces sodium reabsorption, which lowers blood pressure and decreases fluid volume. That fluid reduction is part of why the drug helps with heart failure. Researchers believe the cardiovascular and kidney benefits go beyond just removing extra sugar and fluid, though the full picture of how it protects these organs is still being studied.
Why 25 mg Instead of 10 mg
The starting dose is always 10 mg. Your doctor may increase it to 25 mg if your blood sugar targets haven’t been met. In clinical trials, empagliflozin lowered A1c (a measure of average blood sugar over three months) by 0.7 to 0.9 percentage points when used alone. The jump from 10 mg to 25 mg produces only a small additional A1c reduction, so the higher dose isn’t dramatically more powerful for blood sugar. For heart failure and chronic kidney disease, 10 mg is the standard dose, and the 25 mg dose is specifically positioned as the step-up option for glycemic control.
The tablet is taken once daily in the morning, with or without food.
Cardiovascular Benefits
The landmark EMPA-REG OUTCOME trial, which followed over 7,000 people with type 2 diabetes and existing cardiovascular disease, produced striking results. Empagliflozin reduced cardiovascular death by 38% and cut heart failure hospitalizations by 35% compared to placebo. These benefits were independent of how well it controlled blood sugar, meaning the heart protection wasn’t simply a downstream effect of lower glucose levels.
This trial was the reason regulators expanded the drug’s approved uses well beyond diabetes. For people with type 2 diabetes who already have heart disease, the cardiovascular protection is often the primary reason the drug is prescribed, with blood sugar lowering as a secondary benefit.
Kidney Protection
Empagliflozin significantly slows the rate at which kidney function declines. In the EMPA-REG OUTCOME trial, people taking the drug had roughly two-thirds lower odds of experiencing rapid kidney function loss compared to those on placebo. This protective effect held up across different thresholds of decline.
Current guidelines from KDIGO, the leading international kidney disease organization, recommend starting SGLT2 inhibitors like empagliflozin when kidney filtration rate (eGFR) is at least 20 mL/min/1.73 m², and continuing the drug even if kidney function drops below that threshold, unless dialysis or a transplant becomes necessary. The drug is not effective for blood sugar lowering when kidney function is severely reduced (below 30 mL/min/1.73 m²), but its protective effects on the kidneys and heart persist at lower levels of function.
Empagliflozin is not recommended for people with polycystic kidney disease or those on certain immunosuppressive treatments for kidney conditions.
Common Side Effects
Because empagliflozin pushes extra sugar into your urine, it creates an environment where yeast can thrive. Genital yeast infections are the most characteristic side effect. In clinical trials, about 6.4% of women taking the 25 mg dose developed genital fungal infections, compared to 1.5% on placebo. For men, the rate was 1.6% at 25 mg versus 0.4% on placebo. These infections are generally treatable with standard antifungal medications, but they can be recurrent.
Urinary tract infections occurred at similar rates across the empagliflozin and placebo groups in some analyses, though women had higher baseline rates overall (around 17% in trial populations regardless of treatment group). Increased urination is expected given how the drug works, particularly early on.
Euglycemic Ketoacidosis
The most serious risk to be aware of is a condition called euglycemic diabetic ketoacidosis. This is a dangerous buildup of acids in the blood that normally occurs only when blood sugar is very high. With SGLT2 inhibitors, it can happen even when blood sugar is below 200 mg/dL, which makes it easy to miss. Symptoms include nausea, vomiting, fatigue, shortness of breath, rapid heartbeat, and abdominal pain. Because blood sugar isn’t dramatically elevated, the usual warning signs of extreme thirst, frequent urination, and confusion may be absent.
This complication is uncommon but can be triggered by surgery, prolonged fasting, heavy alcohol use, or illness that causes dehydration. Empagliflozin is not recommended for people with type 1 diabetes because the risk of ketoacidosis is higher in that population.
Who Should Not Take It
Beyond type 1 diabetes, empagliflozin is not recommended for blood sugar management in people whose kidney filtration rate has dropped below 30 mL/min/1.73 m², because the drug can’t effectively clear glucose at that level of kidney function. It can still be used at lower kidney function levels for heart or kidney protection, but not primarily for glucose lowering. People with a history of serious allergic reactions to the medication or who are on dialysis should not take it.